Nick Sireau founded biotech initiatives driven by his sons' rare disease and his own OCD. This highlights how an intimate understanding of an unmet need can be a powerful catalyst for creating focused therapeutic companies, especially in areas neglected by larger players.
Previously thought to be rare, Obsessive-Compulsive Disorder affects 3% of the population, a quarter-billion people. Its true scale was hidden by the intense shame sufferers feel, preventing diagnosis. Big Pharma is now recognizing this vast, underserved market, creating a significant commercial opportunity.
Multiple effective OCD treatments—neurosurgery, deep brain stimulation, and TMS—all directly or indirectly target the anterior cingulate cortex. This convergence of different modalities provides strong biological validation for new drugs that also modulate this specific brain region.
Serenatus Bio is developing a novel COMT inhibitor based on Tolcapone, an old drug that showed efficacy in OCD but had severe liver toxicity. This strategy uses a flawed predecessor's clinical signal as proof-of-concept, de-risking the biological hypothesis while focusing innovation on solving the safety issues.
Serenatus Bio's Phase 1b study for its lead OCD drug incorporates 7-Tesla MRS imaging to directly measure the drug's effect on the brain's glutamate-GABA balance. This provides a clear "target engagement" signal, confirming the biological mechanism before a larger efficacy trial and significantly de-risking the program.
Obsessive-compulsive disorder serves as an archetypal model for compulsivity. Insights from its well-characterized neural circuits offer a lens through which to analyze modern societal issues like social media and gambling addictions, which are fundamentally disorders of compulsivity.
Serenatus Bio develops three distinct drug programs for OCD, acknowledging that no single treatment is universally effective in heterogeneous psychiatric conditions. This multi-asset approach diversifies risk and increases the probability of successfully treating different patient subpopulations.